Interactions between meloxicam and Abciximab (abciximab)
abciximab and meloxicam (Moderate Drug-Drug)
GENERALLY AVOID: The risk of bleeding associated with glycoprotein IIb/IIIa inhibitors is increased in the presence of nonsteroidal anti-inflammatory agents due to additive inhibitory effects on platelet function. Arterial puncture sites may be most problematic. Data are available for abciximab.
MANAGEMENT: It is recommended that these drugs be used together only when indicated by skilled personnel who are qualified and equipped to detect and treat bleeding complications.